Biogen gives investors something else to ponder
The company’s chief financial officer leaves on the eve of its second-quarter earnings report; should investors be worried?
J&J holds its own on sales per employee
Johnson & Johnson is easily the largest big pharma employer, and on certain metrics outstrips smaller rivals.
Crisis, what crisis? Curevac denies everything
As a Covid-19 vaccine exclusivity and senior management storm engulfs Curevac, the German mRNA specialist insists it’s just conjecture and coincidence.
Storm-tossed Qiagen plots a course to higher growth
A shift to higher-growth systems and a tie-up with Illumina are sensible moves, but will take time to pay off.
The extremes converge in big medtech’s hiring practices
Intuitive Surgical makes the most money per employee – but the title of “most improved” goes to Philips.
Warning signs were always there for Novartis’s Avexis deal
High-profile departures at Avexis raise more questions about Novartis’s acquisition, but there were plenty of red flags before the deal was sealed.
